drugset / Trial / NCT03527147
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's Lymphoma (NHL).
Timeline
- Start
- 2018-06-19
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5153 | Small molecule | — | Oral |
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Subject | Ceralasertib | Small molecule | — | Oral |
| Subject | Danvatirsen | Antisense oligonucleotide | — | Intravenous |
| Subject | Magrolimab | Monoclonal antibody | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |